A patient with metastatic collecting duct carcinoma achieved stable disease and significant pain relief after personalized neoantigen peptide vaccination and T-cell therapy, with 12/13 neoantigen-targeted tumor clones reduced.
92%of neoantigen-targeted tumor cell populations showed decreased mutant allele frequency after treatment
What the researchers found
After 6 cycles of neoantigen peptide vaccination and neoantigen-reactive T cell therapy, the patient achieved stable disease with significant pain relief. Post-treatment biopsy showed decreased mutant allele frequency for 92% (12/13) of targeted neoantigens.
Why it matters
This is the first demonstration that personalized neoantigen immunotherapy can work in collecting duct carcinoma, one of the most treatment-resistant cancers. The 92% neoantigen-targeted clone reduction is striking evidence of specific anti-tumor immunity.
The numbers in context
1 patient; personalized neoantigen vaccine; clinical response achieved in a cancer with no standard therapy.
How the study worked
Case report of a metastatic CDC patient. Tumor whole-exome sequencing identified 13 neoantigens. Long-peptide vaccine and neoantigen-reactive T cells (NRTs) prepared. Six treatment cycles administered. Monitored by imaging, pain assessment, IFN-γ ELISPOT, and tumor biopsy with allele frequency analysis.
Who was studied
Single patient with advanced collecting duct carcinoma of the kidney
What this study cannot tell us
Single case report — cannot establish generalized efficacy. Stable disease rather than tumor regression. The relative contributions of peptide vaccination versus T-cell therapy are unclear. Long-term outcomes not reported.
How to read the evidence
Single case report with strong molecular evidence of immune-mediated tumor targeting. Compelling proof-of-concept but cannot establish efficacy at population level.
When this study was published
Published in 2020. Personalized neoantigen vaccines have continued to advance in clinical trials for various cancer types.
The bigger picture
Personalized cancer vaccines represent the frontier of precision oncology. This case demonstrates their potential even in rare cancers with low mutation burdens, expanding the patient population that could benefit from neoantigen-based immunotherapy.
Questions still open
- Can personalized neoantigen therapy be scaled for broader CDC patient populations?
- Would earlier administration (before tumor progression) produce better outcomes?
- What is the optimal balance between peptide vaccination and adoptive T-cell therapy?
Common questions
What is a neoantigen?
What is collecting duct carcinoma?
Read the original research
Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
Journal for immunotherapy of cancer, 8(1)
Citation
Zeng, Yongyi; Zhang, Wei; Li, Zhenli; Zheng, Youshi; Wang, Yingchao; Chen, Geng; Qiu, Liman; Ke, Kun; Su, Xiaoping; Cai, Zhixiong; Liu, Jingfeng; Liu, Xiaolong. (2020). Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.. Journal for immunotherapy of cancer, 8(1). https://doi.org/10.1136/jitc-2019-000217